Skip to main content
Fig. 4 | Clinical Proteomics

Fig. 4

From: Highly sensitive therapeutic drug monitoring of infliximab in serum by targeted mass spectrometry in comparison to ELISA data

Fig. 4

Testing and optimizing enzyme hydrolysis of the antibody: (A) Calculated digest yield of both investigated peptides with different trypsins in a plasma sample matrix. (B) Digest yield of the peptides of choice after different incubation times for proteolysis. (C-D) Calibration curves of the SINSA peptide of infliximab. Curves were generated and measured by two different researchers with a time difference of 6 month. Both calibration curves show robust results in regard to their LOD and LLOQ. Each calibration point was measured 3 time with independent replicates. (E-F) Results of the absolute quantification of the peptides shown in 8 different patient samples (serum). Shown are the antibody concentrations determined by an ELISA (dashed line) and the measured values obtained by mass spectrometry in comparison (black bars). The measurements were carried out on identical samples from each patient

Back to article page

Clinical Proteomics

ISSN: 1559-0275